N/A
Manufactured by Apotex Corp.
6,602 FDA adverse event reports analyzed
Last updated: 2026-04-15
FINGOLIMOD is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Apotex Corp.. The most commonly reported adverse reactions for FINGOLIMOD include MULTIPLE SCLEROSIS RELAPSE, LYMPHOPENIA, MULTIPLE SCLEROSIS, DRUG INEFFECTIVE, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FINGOLIMOD.
Out of 4,082 classified reports for FINGOLIMOD:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 6,602 FDA FAERS reports that mention FINGOLIMOD. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include MULTIPLE SCLEROSIS RELAPSE, LYMPHOPENIA, MULTIPLE SCLEROSIS, DRUG INEFFECTIVE, FATIGUE, COVID-19. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Apotex Corp. in connection with FINGOLIMOD. Always verify the specific product and NDC with your pharmacist.